Investor Presentaiton

Strategic Benefits: The acquisition has several key strategic benefits Expected to bring additional scale in two significant target markets of NSW and QLD Scale NSW is the largest market in Australia and QLD is number three Leverage from existing scale and excellent geographic bolt on ACL has a number of national customers that it hasn't been able to service in QLD and across NSW Customer • ACL / Medlab combined will enable a full service offering in mainland states Service • ACL will be able to compete more effectively for national tenders Key Subspecialty benefits ACL has significant strength in skin histopathology through its acquisition of Sun Doctors and its specialists in each State ACL has gastroenterology leadership through its gastro specialists and inpatient coverage Medlab has leading skin and gastroenterology pathology specialists to enhance ACL strengths in QLD and NSW QLD Entry ACL has a QLD molecular laboratory (COVID testing for symptomatic patients and travellers) - this will facilitate Medlab's COVID offering • Medlab has an established clinical and histopathology lab in Brisbane, Sun Doctors a histopathology lab at the Gold Coast Medlab Brisbane will enable enhanced service for the ACL purpose built Clinical Trials laboratory 4

View entire presentation